Collaboration on lonodelestat in COVID-19-related ARDS

27 April 2020
santhera-large

Shares of Swiss biotech firm Santhera Pharmaceuticals (SIX: SANN) were up 26.75% to 10.14 Swiss francs in early trading, after the company announced a COVID-19 related collaboration.

Santhera has joined forces with Cold Spring Harbor Laboratory (CSHL) to investigate lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome (ARDS), a frequent result of the novel coronavirus.

The company acquired rights to POL6014 in 2018 from fellow Swiss firm Polyphor, in a deal that involved an upfront payment of around $7 million plus additional cash payments of up to 121 million francs ($124 million) contingent on future development, regulatory and particularly sales milestones

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology